Filmmaking Accessories Manufacturer Makes Game-Changing Pivot to Create Innovative Mask Dispensers

The manufacturer, Zacuto, is well-known in the filmmaking industry for its innovative designs.

CHICAGO, IL, USA, September 23, 2020 /EINPresswire.com/ — Renowned filmmaking accessories manufacturer, Zacuto, is pleased to announce it has made a dramatic addition to produce an innovative mask dispenser with its brand-new sister company, Zacuto PPE.

Zacuto PPE is a division of Zacuto, a Chicago-based filmmaking accessories manufacturer of over 20 years. Zacuto is known in the filmmaking industry as a company with sleek inventions and innovative designs, while boasting outstanding customer service.

In the company’s most recent news, Zacuto is excited to announce a recent pivot to also design and manufacture medical equipment and distribute its most recent product – the disposable face mask dispenser. The face mask dispenser is a quality aluminum dispenser that holds 250 of the company’s unique, individually wrapped 3-ply disposable face masks.

“We felt it was important to change our position during the ongoing pandemic as we saw a need for this type of product,” says Mandy Rogers, VP of Sales & Marketing. “With this vision in mind, we went to work to design and manufacture a disposable face mask dispenser that can be used in a wide variety of offices, hospitals, schools, businesses, and other public spaces. Now, more than ever, customers and employees need to feel safe, and our face mask dispenser is the ultimate way to safely provide individuals with the disposable face masks they need.”

During the design process, the team at Zacuto ensured no design elements were missed and, as such, its face mask dispenser boasts a host of useful features and benefits, including:

· Easy set up and refill
· Sturdy and attractive aluminum structure
· Spring-loaded to ensure only one mask can be taken at a time
· Holds up to 250 individually wrapped masks
· Works seamlessly with Zacuto’s disposable face masks
· Small space-saving design
· An innovative design that allows the user to only touch their mask and not the machine or other masks to prevent virus spread
· Customizable graphics to brand the machine, allowing sponsors to pay for advertising which, in turn, pays for the masks
· Masks can have stickers on the wrapping to act as coupons, turning the dispenser into a marketing campaign with advertisers paying for the masks

“The first dispenser was put out by the employee entrance,” says one of Zacuto PPE’s clients, a Supply Chain Analyst at an east coast hospital. “Since its inception, there has been a reduction of upwards of 1000 masks a day. I think this will make a huge difference in our supply costs. It also looks WAY better than having boxes of masks around. Senior management is VERY pleased by the craftsmanship and sturdiness of the dispenser. They like it a lot.”

For more information about Zacuto PPE, please visit www.zacutoppe.com.

About the Company

Zacuto is a USA-made, production-grade filmmaking camera accessories and rigs manufacturer. Owners and designers, Steve Weiss & Jens Bogehegn, who are filmmakers themselves for 37 years, design their filmmaking equipment for filmmakers to provide the proper shooting experience. Starting in 2019, Zacuto moved into additionally creating consumer products, apps, and medical supplies, as well as maintaining its lead in film equipment design.

Mandy Rogers
Zacuto
+1 312-863-3456
email us here


Source: EIN Presswire

New study on Copper, best prevention for COVID-19 Community Transmission

USA, September 23, 2020 /EINPresswire.com/ — Despite months of lockdown, cases of COVID-19 are rising fast in countries from the U.S. to Brazil and India. The resulting economic downturns, and mental health crises, have meant that few want to bunker down again. But with death tolls continuing to soar and the virus showing no signs of abating before a vaccine is released, something has to change.

Professor Bill Keevil, a renowned microbiology expert at the University of Southampton, says we need to start safeguarding our public spaces. While he agrees that using masks and sanitizers are good measures for personal safety, he says that more should be done to reduce community transmission by contaminated surfaces- whether in hospitals, public transit points, schools, factories, or homes.

And there's one material that rises above others to help us do this: copper, the well-known metal used to make brass coins.

In a 2015 study, Keevil found that copper was able to kill Coronavirus 229E, a close relative of COVID-19, in under 5 mins. But how? When viruses and bacteria land on the metal, its particles blast at them like a revolving gun, punching holes in their outer layers that prevent them from breathing.

Most importantly though, copper particles seek and destroy their DNA and RNA, essential for coding the cells’ inner workings. As Keevil says, the metal essentially kills viruses and bacteria by 'blowing them apart'.

The effectiveness of copper at defending against superbugs has been backed up by other studies too. Research funded by the U.S. Department of Defense found that using the material on hospital surfaces including bedside rails, tray tables, intravenous poles, and chair armrests, reduces hospital-related infections by 58%.

This is significant given close to 100,000 Americans die from infections contracted in hospitals every year, costing an estimated $45 billion. The results from this research thus mean that if copper surfaces were used more commonly in hospitals, the U.S. could save over $26 billion in healthcare costs, and almost 60,000 lives.

And this is nothing new. The antiviral and antibacterial effects of copper have been known for over eight millennia. With its first known use as an infection-killing agent dating back to 3200 B.C. in Egypt, the Chinese are also known to have used the metal as a medication for heart, stomach, and bladder problems from as early as 1600 B.C.

Even New York City's Grand Central Terminal, at over 100 years old, is lined with copper railings- with recent experiments by Keevil having shown them to have the same antimicrobial properties when first installed. Not only has the metal been widely used for its antimicrobial properties across the ages, but it also seems to maintain these properties for just as long.

Despite its long-standing antimicrobial reputation, interest in the metal’s potential to help during the COVID-19 pandemic waned following the publication of a study in The New England Journal of Medicine. In it, researchers found that copper surfaces took 4 hours to kill SARS-CoV-2.

Although still significantly better than plastic and stainless steel, on which the virus remained intact for more than 72 hours, it's still a far cry away from earlier studies showing that copper kills germs in minutes.

When asked why this was the case, Keevil said that some differences come as the studies observed different viruses. While the new study looked at the novel coronavirus, his research studied a closely-related cousin.

Most importantly, though, Keevil said while the new study used L-glutamine (a supplement used to keep cells alive during lab experiments) to grow the COVID-19 in human cells, he used GlutaMAX. Unlike GlutaMAX, L-glutamine binds to copper, thereby reducing its antimicrobial effects.

This, says Keevil, may explain why copper seemed to act slower than expected against COVID-19 and that, under natural conditions, the metal may still be able to fend off SARS-CoV-2 much faster than recorded.

And a recent study may have just proven this to be the case. An analysis of copper against the virus from Brazil found that while ethanol is able to eliminate 80% of SARS-CoV-2 particles within 30 seconds, a certain variety of copper manufactured by Brazilian firm ‘Biocobre’, is able to kill 77% of SARS-CoV-2 virus particles within two minutes.

"My team and I have been aware of the potential for a global pandemic for years and thus have been researching the effects of copper for some time," says Felipe Kavaleski, CEO of Biocobre.

"Although it has proven to be highly effective in many studies, the cost barrier for installing copper in public places has been a major reason why it's not more widespread- both in Brazil and all over the world."

He continued to say that practicality presents a big issue too: "It's just not practical to ask specialists each time to replace public surfaces.”

Made out of 99% copper, Biocobre is a copper layer that can be applied to surfaces and appliances like a sticker. Preliminary tests have also found that the material is able to kill off over 95% of virus particles- including SARS-CoV-2- in under 10 minutes, alongside a host of other harmful bacterias thanks to its scraped surface.

Beyond Biocobre, others are also starting to apply the benefits of copper to public health. For example, Australian company, Spee3D, has created machines that spray copper particles onto door handles and push plates. Meanwhile, Chilean company, Aintech, has created a disinfectant spray with copper as a key ingredient.

Although individually these solutions may make up a small part of a bigger picture, collectively, they may play a critical role in curbing community transmission of COVID-19. Alongside other safety precautions such as proper hygiene and wearing masks, lining our public spaces with copper whether by copper-paneling, adhesive stickers or spray, may be integral for evading on-off lockdowns and ultimately, returning to some normality.

Felipe Kavaleski
Biocobre
+1 786-238-3035
email us here


Source: EIN Presswire

Dr. Sung Yang Explains How Preventing Severe COVID-19 Cases is About Controlling Chronic Conditions

Dr. Sung Yang Explains How Preventing Severe COVID-19 Cases is About Controlling Chronic Conditions

COVID-19

In an Effort to Reduce Severe COVID-19 Cases, Dr. Sung Yang Explores Existing Chronic Conditions

HONOLULU, HI, UNITED STATES, September 23, 2020 /EINPresswire.com/ — Throughout the history of COVID-19, medical professionals have noted that most people with severe cases have other health problems. Those who are healthy will often encounter only mild to moderate flu-like symptoms. Dr. Sung Yang explores how managing existing chronic conditions can help prevent severe COVID-19 cases.

Dr. Sung Yang is a physician based in Honolulu, Hawaii. He has been exploring a number of aspects regarding COVID-19, including the way to prevent severe infections. He has found that by working with his patients, it’s possible to reduce the risk of severe COVID-19 cases with complications.
One of the things that Dr. Sung Yang recommends is identifying the various chronic medical conditions that a person has. Particularly as it pertains to CovidOVID-19, certain conditions can make the virus to become more aggressive or the immune system more vulnerable to the virus. Dr. Sung Yang explains that many of these conditions are already familiar and include but not limited to diabetes, high blood pressure, obesity, coronary artery disease, asthma, COPD, chronic kidney disease, and cancer.

Not all patients have their chronic conditions under control. Now more than ever is the time that Dr. Sung Yang recommends that patients need to achieve maximum control. In some instances, it may be necessary to focus on medications. In other instances, it is necessary to transform the lifestyle by eating healthy, exercising more and losing weight.

A patient who has chronic conditions that are out of control are more likely to have a rough go of time with COVID-19. The patient who tested positive for COVID-19 may need to stay in a hospital or even transfer to the ICU because he or she has difficulty with breathing that causes hypoxia, which is a critical drop in oxygen level in the circulation. Therefore, the patient needs to be connected to a ventilator machine to receive more air and oxygen through the lungs weakened and damaged by the virus. When not enough oxygen is absorbed from the lungs and transported into the circulation other vital organs such as the heart, brain, and kidneys start to not work properly and go into multiple organ failure. At the same time, the immune system becomes exhausted after fighting with the COVID-19 virus and becomes so weakened that it cannot fend off other infections by other bacteria and viruses such as the flu virus. Lastly, the immune system also becomes so altered that it behaves strangely in such a way that it allows clots to form in various blood vessels and organs even though such clots are not needed. All of these complications add more time, medications, procedures as well as more suffering to the hospitalization and even death in many unfortunate scenarios.

Dr. Sung Yang has a goal to keep his patients out of the ER, the hospital and of course the ICU. By helping patients better control their chronic conditions Dr Sung Yang keeps the COVID-19 patients quarantined at home with just mild symptoms. Dr. Sung Yang believes that education is the key. During regular in-person or telemedicine visits Dr. Sung Yang emphasizes this prevention against severe COVID-19 infections.

In addition to focusing on optimizing the control of chronic conditions, Dr. Sung Yang is also an advocate of rapid and accurate COVID-19 testing. He believes that patients will have a better chance of avoiding the coronavirus entirely if it’s possible to know who has been exposed to the virus.
Dr. Sung Yang recommends that anyone with chronic medical conditions focus on getting them under maximum control now rather than later because once a person is hospitalized due to severe COVID-19 infection it is too late.

Caroline Hunter
Web Presence, LLC
+17862338220
email us here


Source: EIN Presswire

BioPharm America™ Digital 2020 Startup Pitch Competition Winner: Ciscovery Bio Inc.

CARLSBAD, CA, USA, September 23, 2020 /EINPresswire.com/ — BioPharm America™ Digital 2020 Startup Pitch Competition Winner: Ciscovery Bio Inc.

• Ciscovery Bio Inc. is a biotech startup that specializes in the discovery and commercialization of non-coding biomarkers for drug discovery and precision medicine.

• Five short-listed life sciences startups pitched to an expert judging panel at the BioPharm America™ Digital 2020 Startup Pitch Competition

Carlsbad, CA, September 23, 2020 – Ciscovery Bio Inc. was announced the winner of the 13th annual Startup Pitch Competition at BioPharm America™ Digital. The startup company based in Philadelphia, Pennsylvania, provides solutions to assist biopharma companies in screening drug candidates at early stages of drug development and precision medicine companies in better predicting the drug responses of individual patients. It systematically and experimentally identifies a large number of gene regulatory elements from multiple cell types and uses these as non-coding biomarkers for in vitro drug screening and identifying patient-specific, functional non-coding variants.

“We unlock the non-coding genome that takes 98% of the human genome for biomarker discovery with our genome-scale discovery tool. Our extensive collection of non-coding biomarkers allows us to comprehensively monitor drug-induced cellular changes and to better predict personal variations in drug response,” explains Joonyul Kim, Founder and CEO of Ciscovery Bio Inc.

During the competition, innovative entrepreneurs from five life science startups pitched their company to leading authorities in the global biotech industry in a digital format that was also available to the delegates attending the BioPharm America Digital event this week. Other pitch contestants included: Ardan Pharma, MediGear International Corporation, Element Therapeutics Company, and EndoCrine. The company pitches were evaluated by an expert panel of judges which consisted of Mira Chaurushiya, Ph.D., Partner at 5AM Ventures, Anjali Kumar, Sr. Director External Innovation Search and Evaluation at Johnson & Johnson Innovation, Matthew Miessau, Associate with Epidarex Capital, and Anna Turetsky, Principal, Venture Investments at The Mark Foundation for Cancer Research.

“Winning at BioPharm America certainly provides the high level of confidence for me and for my team as we are at a product-market fit and customer discovery stage. This honor confirms that we are on the right track. Now that we are ready for the next stage to maximize the value of our technology, the recognition from this win will help us get more traction and connect with customers and partners who we couldn't have reached otherwise. We are honored, and humbly accept that this win means that we will get busier, which is a fantastic thing to happen for us,” says Joonyul Kim, Founder and CEO of Ciscovery Bio Inc.

As the winner of the Startup Pitch Competition, Ciscovery Bio Inc.’s CEO and pitch competition presenter, Joonyul Kim, received a ticket to any upcoming EBD Group partnering event of his choice.

About EBD Group
EBD Group’s overriding mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, partneringONE®, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings.

Today our events (BIO-Europe®, BIO-Europe Spring®, BioPharm America™, Biotech Showcase™, China Showcase, Digital Medicine & Medtech Showcase, ChinaBio® Partnering Forum, Rare Disease Innovation and Partnering Summit, and BioEquity Europe) annually attract more than 15,000 senior life science executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry.

EBD Group is an Informa company. For more information please visit www.ebdgroup.com.

Media contact:
Kari Bennett, EBD Group: +1 760 930 0500; kbennett@ebdgroup.com

Kari Bennett
EBD Group
+1 760-930-0500
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Dr. Frank Roach, Atlanta Dentist, Discusses the Top 3 Signs You Need to See a Dentist

Dr. Frank Roach

Dr. Frank Roach

ATLANTA, GA, UNITED STATES, September 23, 2020 /EINPresswire.com/ — Dr. Frank Roach Atlanta dentist sees dozens of patients every day, and over his two decades of experience, he has learned what symptoms can wait and which mean you need to see a dentist immediately.

See Your Dentist If You’re Experiencing Tooth Pain Says Dr. Frank Roach Atlanta Dentist

“Toothaches are always a sign that something deeper is wrong,” says Dr. Frank Roach Atlanta dentist. He explains that temporary, random, or passing pain is likely nothing to worry about. “You may just have some tooth sensitivity.”

But if you are experiencing prolonged, sharp, or worsening pain, it’s time to call the dentist. “Typically your pain is only going to worsen over time,” says Dr. Frank Roach Atlanta. “And if it’s an infection or an abscess, you’re risking it spreading to other areas of your mouth. That’s a much more painful and expensive treatment process.”

If You Find White Spots On Your Gums or Teeth Seek Treatment Says Dr. Frank Roach Atlanta

If you see white spots on your teeth, you should schedule a dentist appointment, says Dr. Frank Roach Atlanta. White spots on your tooth’s enamel are one of the first signs of tooth decay. “If you catch it early, you can prevent a cavity – and possibly having to undergo the drilling and filing process.
“It’s so much cheaper to treat the problem proactively than it is to deal with the aftermath,” says Dr. Roach.

On your gums, white spots are a sure sign of infection. “You may not have any pain in your tooth yet, but it’s coming for you if you have white spots on your gums,” says Dr. Frank Roach Atlanta. He advises you not to pop or scrape the spot as you could inadvertently spread infection. Instead, call your dentist right away.

Dry Mouth Can Be a Warning Sign Says Dr. Frank Roach Atlanta

“Dry mouth can be caused by any number of conditions or medications,” says Dr. Roach. But while dry mouth is a common experience, consistent and repeated dry mouth can be a sign of chronic conditions. And no matter what causes it, dry mouth can cause gum disease and promote bacterial growth. Schedule an appointment with your dentist to discuss treatment options. Medicated mouthwashes can help tremendously with dry mouth aggravation and symptoms.

Dr. Frank Roach Atlanta dentist has been serving Atlanta for over 20 years. He constantly strives to stay at the top of his profession by using the latest techniques, materials, and technology. He takes great pride in providing the best dental care available.

Caroline Hunter
Web Presence, LLC
+1 786-233-8220
email us here


Source: EIN Presswire

Digital Currencies – The Future of Payments … Our Soul Searching Thoughts @ Payments2.0

The Future of Payments

The Future of Payments

Payments2.0 Logo

Payments2.0 Logo

My First Card - Smart Kid

My First Card – Smart Kid

Payments2.0 Digital Wallet

Payments2.0 Digital Wallet

We Are Crypto Ready

We Are Crypto Ready

Digital Currencies – The Future of Payments … Our Soul Searching Thoughts @ Payments2.0

My personal conviction on the issue of stable coins is that we better be ahead of the curve. There is clearly demand out there that we have to respond to.”

— ECB President Christine Lagarde

DUBAI, UNITED ARAB EMIRATES, September 23, 2020 /EINPresswire.com/ — Still in their infancy, digital currencies have the potential to radically change payments, banking, central banking, and the balance of economic power.

Today’s adoption rates could, and likely will, change. If the Chinese government, along with Google, Amazon, Facebook, or Apple (the so-called GAFA group), or a Chinese company like Tencent or ANT can overcome some of the barriers to cryptocurrencies, then cryptocurrencies could become more appealing. This will hasten their adoption and give them the potential to replace cash.

My personal conviction on the issue of stable coins is that we better be ahead of the curve. There is clearly demand out there that we have to respond to stated ECB President Christine Lagarde.

Our in-depth research shows the adoption rate of blockchain wallets as compared to the adoption rate of the Internet. At least for now, the curves are similar after adjusting for scale. If current trends continue, there could be two hundred billion blockchain wallet users by 2030. This is something for all of us to think about seriously!

Our twentieth-century payment system needs to be upgraded and digitised. Governments, particularly those in Western countries need to wake up before it is too late. That is because a private, loosely regulated digital currency is probably not the best response to the coming financial disruption.

Now at Payments2.0 we have been striving at addressing the future of payments and developed a solution not just using cutting-edge technology but also practical usage to make it commercially viable for one and all the stakeholders involved including the Customer who is King now.

Our Payments2.0 platform versatile capabilities include
* PAYMENT PROCESSING
Our end to end payments processing solution improves efficiency simplifying operations

* DIGITAL WALLETS
Digital wallet solutions are about more than convenience, creating an alternate banking ecosystem

* DIGITAL CARDS
Take advantage of Digital payment cards to suit your needs – prepaid cards, multicurrency cards, Stored value cards, FX travel cards

* BLOCK CHAIN
Crypto currency wallets linked with regular multicurrency wallets enabling faster and secure transfers

* MULTICURRENCY PLATFORM
Flexibility to store permissible multi currencies with freedom to convert and load between wallets to complete the transaction.

*REMITTANCES
Enabling faster cross border remittances using digital wallets and block chain technology.

* FIAT TO CRYPTO PAYMENTS
Global users can now pay with Crypto using their regular card linked to their multicurrency wallet.

* BUY CRYPTO WITH CREDIT CARD
Our card processing solution and seamless integration with Crypto exchanges facilitates global users to buy crypto coins using credit cards.

* A REWARDS MECHANISM
Our Rewards mechanism can be tailored not just for customers but even to keep staff loyal.

Brands that want to cater to a diverse market need to offer a variety of purchase options. For this reason, customised loyalty apps are popular at major chains. This type of payment system can easily be developed for any company by purchasing basic technology tools. For example, QR codes linked to digital wallets gaining popularity in emerging economies, where people are getting accustomed to this new lifestyle.

Applications can optimise business logistics, personalise customer experiences, and provide data needed for making decisions. For certain businesses, going cashless and adopting the newest technologies can significantly reduce operational overhead, increase productivity, and help with logistics. Software is available for business owners to access data in real-time from mobile devices and generate customisable reports.

Payments2.0 with it's Comprehensive Converged Payment Solutions Suite can provide you Anytime, Anywhere, Anyway, Any Currency!!!

Rohan Francis Britto
Rijndlpay Technologies Pvt. Ltd
+971 55 635 0635
email us here


Source: EIN Presswire

Especialistas del INTI diseñan tecnología 100% argentina para test de Covid-19

del INTI y de la empresa nacional Ivema

MEXICO, September 23, 2020 /EINPresswire.com/ — Se diseña un equipo imprescindible para las pruebas de diagnóstico rápido, que permite sustituir importaciones, reducir costos a la mitad y abastecer la demanda interna que hoy encuentra faltante de stock. Se trata de un dispositivo termobloque que se utiliza para el tratamiento térmico de muestras para detectar la presencia del virus.
En el marco de la actual pandemia y ante el aumento de casos, una de las acciones clave para controlar la propagación del coronavirus es la realización de test. En este escenario, diversos grupos de investigación nacionales desarrollaron con éxito kits de diagnóstico molecular para la detección rápida del virus SARS-CoV-2 y especialistas del INTI tomaron contacto con el sector para conocer sus requerimientos.

“Se identificó que los kits requerían de un termobloque específico para realizar la amplificación molecular de las muestras de ARN sin que hubiese condensación durante el proceso que presentaba un faltante de stock en el mercado nacional y frente a la solicitud de la empresa Ivema Desarrollos para salir en un corto plazo con un equipo de estas características, se decidió trabajar en ello de manera conjunta. Su disponibilidad resultaba clave para ampliar la cantidad de laboratorios y establecimientos en condiciones de realizar los test en el país”, detalla Mijal Mass, de Micro y Nanotecnologías del INTI, integrante del equipo que llevó adelante este trabajo en articulación con los sectores de Biotecnología, Física y Mecánica del Instituto.
"Nos pusimos a trabajar con el INTI y la experiencia fue muy positiva porque pudimos resolverlo en un mes. Hoy ya estamos lanzando la primera serie de 20 unidades y proyectamos satisfacer a lo largo del año una demanda que podría alcanzar los 600 equipos”, detalla Javier Balian, presidente de Ivema Desarrollos.
El nuevo producto responde a los requerimientos específicos del kit “ELA-CHEMSTRIP” que en menos de una hora permite detectar si una persona tiene Covid-19 a partir de un hisopado, pero podrá utilizarse también para otros (como el NEOKIT TECNOAMI) por la precisión para el control de temperatura y porque su precio representa la mitad de los importados. Su característica principal es que posee un sistema de tapa calefaccionada, control digital, excelente uniformidad térmica y permite procesar hasta 24 muestras a la vez.

En relación a la performance del equipo, el coordinador del desarrollo del “ELA-CHEMSTRIP”, Diego Comerci, destaca que cuando sus clientes les consultan lo recomiendan como el ideal. "Además, es un buen ejemplo de cómo se pueden integrar y armar clusters industriales en relación a ciertas tecnologías, como en este caso del sector biomédico y biotecnológico", suma.
En la misma línea, el director del área de Micro y Nanotecnologías del INTI, Alex Lozano, concluye que "se logró en corto tiempo desarrollar un dispositivo adaptado a los requerimientos específicos del test y en condiciones de ser fabricado y comercializado por una empresa nacional. Esto permite abastecer la demanda del mercado local, sustituir importaciones y un mayor acceso a la realización de las pruebas de diagnóstico".

“ELA-CHEMSTRIP”: test diagnóstico molecular del Covid-19
– Kit desarrollado a partir de una alianza estratégica entre las empresas Chemtest, Productos Bio-lógicos (PB-L) y las universidades nacionales de San Martín (UNSAM) y Quilmes (UNQ).
– Permite la detección del virus SARS-Cov2 de forma más simple que las tradicionales RT-PCR y en menor tiempo (estimado en una hora).
– El ensayo resulta ideal para implementar en forma descentralizada en instalaciones de escasa infraestructura sanitaria.
– Hasta el momento llevan distribuidas alrededor de 110 mil determinaciones, entre el sector público y el privado, concentradas mayoritariamente en el Área Metropolitana de Buenos Aires.
– La capacidad de producción es de 120 mil test por mes.

Acerca de Stratasys
Por casi 30 años, Stratasys Ltd. ha sido una fuerza determinante en la impresión 3D manufactura aditiva moldeando la manera en que las cosas son hechas. Con sede en Minneapolis, Minnesota y Rehovot, Israel, la compañía empodera a los clientes en los mercados verticales, incluyendo Aereoespacial, Automotriz, Cuidado de la Salud, Educación y Productos de Consumo, permitiendo nuevos planteamientos para el diseño y la manufactura. Las soluciones de Stratasys ofrecen libertad de diseño y flexibilidad de la manufactura al reducir el plazo de lanzamiento y disminuyendo los costos de desarrollo y a la vez, mejorando los productos y la comunicación. reconocimientos en tecnología y liderazgo. En línea se encuentra en www.stratasys.com, www.stratasys.com/mx, http://blog.stratasys.com/. Síganos en LinkedIn. Stratasys se reserva el derecho de utilizar cualquiera de las plataformas de redes sociales anteriores, incluidos los sitios web de la compañía, para compartir información material no público de conformidad con el reglamento. En la medida necesaria y ordenada por la ley aplicable, Stratasys también incluirá dicha información en sus presentaciones de divulgación pública. Stratasys, FDM, F900 y Nylon 12 FC son marcas comerciales registradas de Stratasys Ltd. y/o sus filiales. Todas las demás marcas comerciales son propiedad de sus respectivos dueños, y Stratasys no asume ninguna responsabilidad con respecto a la selección, el rendimiento o el uso de estos productos.

Contacto de Prensa México; Agencia PR:
Liliana Pérez: +5252948215. Liliana@lizetteweber.com www.lizetteweber.com

Lizette Weber
Lizette Weber PR Agency
+52 5566285614
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Antibiotics Market to Reach $50.37 Billion by 2025 at 2.1% CAGR

Antibiotics Market

Antibiotics Market

Rise in consumption of antibiotics in low & middle-income countries heavy investments for R&D by biotech companies would propel the growth of antibiotics market

PORTLAND, OR, UNITED STATES, September 23, 2020 /EINPresswire.com/ — Allied Market Research published a report, titled, Antibiotics Market by Class (Beta Lactam and Beta Lactamase Inhibitors (Penicillins, Cephalosporins, Carbapenems, and Monobactams), Quinolones, Macrolides, and Others), Drug Origin (Natural, Semisynthetic, and Synthetic), Spectrum of Activity (Broad-spectrum antibiotic and Narrow-spectrum antibiotic), and Route of Administration (Oral, Intravenous, and Others): Global Opportunity Analysis and Industry Forecast, 2018-2025. The report provides detailed analyses of the top winning strategies, driving forces & opportunities, key market segments, competitive landscape, and strategic developments. As per the report, the global antibiotics market generated $42.33 billion in 2017 and is expected to reach $50.37 billion by 2025, registering a CAGR of 2.1% from 2018 to 2025.

Increasing utilization of antibiotics in low and middle-income countries (LMICs) due to high incidence of severe infections, high capital allocation for R&D activities by biotech companies, and supportive norms and regulations drive the growth of the market. However, development of antibiotic resistance and rise in drug approval costs hinder the market growth. Conversely, discovery of advanced prospect molecules and innovative combination therapies for the treatment of antibiotic-resistant microbial infections would create opportunities for the market in future.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/5072

Beta lactam and beta lactamase inhibitors segment to maintain its dominance by 2025

The beta lactam and beta lactamase inhibitors segment contributed nearly two-thirds of the total market share in 2017 and is expected to maintain its dominance by 2025. This is due to rise in demand for its effectiveness in treating Gram-positive & Gram-negative bacteria as well as use in the treatment of broad-spectrum of infections. However, quinolones segment would register the fastest CAGR of 4.3% from 2018 to 2025, owing to their characteristics such as remarkable oral bioavailability, good tissue penetration, and high broad-spectrum bactericidal activity, especially in new generation quinolones. The report also analyzes macrolides and others.

Semisynthetic segment to lead throughout the forecast period

The semisynthetic segment accounted for more than one-third of the total market share in 2017 and will continue to maintain its lead by 2025. This is due to the enhanced coverage and efficacy against a wide range of organisms as well as ease in administration and cost effectiveness as compared to other antibiotics. However, the synthetic segment would register the fastest CAGR of 2.7% from 2018 to 2025 due to high demand for synthetic membrane-targeted antibiotics, broad spectrum activity, rapid bactericidal activity, no cross-resistance with existing antibiotics, and low probability of developing resistance. The report also discusses antibiotics of natural origin.

Broad-spectrum antibiotics segment to be lucrative by 2025

Broad-spectrum antibiotics segment contributed more than two-thirds of the total market share in 2017. This segment would dominate by 2025, registering the fastest CAGR of 2.4% from 2018 to 2025. This is attributed to the growing demand for broad-spectrum antibiotics to curb widespread antimicrobial resistance. The research also discusses narrow-spectrum antibiotics.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/5072

Intravenous segment to dominate in terms of revenue during the forecast period

Intravenous route of administration segment accounted for nearly half of the total market share in 2017, owing to the rise in incidence of severe infections, which requires intravenous antibiotics for reaching the tissues faster and achieving higher concentrations as compared to oral antibiotics. This segment would maintain its lead position by 2025. However, the oral segment would grow at the highest CAGR of 2.5% from 2018 to 2025, owing to ease in self-administration, which results in high demand for oral drugs and reduction in hospital stay.

Asia-Pacific to register the highest revenue by 2025

Asia-Pacific region contributed more than one-third of the total market share in 2017, owing to the burgeoning rate of antibiotics consumption, ease in availability of antibiotics, and increase in sales of antibiotics without prescription. This region would continue to dominate throughout the forecast period. However, LAMEA region would grow at the fastest CAGR of 3.5% from 2018 to 2025. This is due to easy of availability and relaxed legislations or restrictions on their usage in this region.

Leading market players

The key market players analyzed in the report include Abbott Laboratories, F.Hoffmann-La Roche Ltd., Allergan Plc., Merck & Co. Inc., GlaxoSmithKline plc, Novartis International AG (Sandoz), Mylan N.V., Sanofi, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. They have implemented various strategies such as expansions, mergers & acquisitions, joint ventures, partnerships, collaborations, and others to achieve a strong position in the industry.

Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at: https://www.alliedmarketresearch.com/knowledgetree

Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.

Similar Reports:
Global Spirulina Market Expected to Reach $779 Million by 2026
Global Healthcare Chatbots Market Expected to Reach $116.9 Million by 2026

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Intravenous Therapy and Vein Access Market Size Targets to Grow at a CAGR of 6.4%& to Hit $27,971 Million by 2026

IV therapy works faster for the quick immune system response and relief from chronic diseases as compared to oral mode of medication

PUNE, MAHARASHTRA, INDIA, September 23, 2020 /EINPresswire.com/ — Intravenous therapy is used to administer medicine, nutrients, blood, and buffer solution directly into the vein. IV therapy works faster for the quick immune system response and relief from chronic diseases as compared to oral mode of medication. IV therapy can be easily monitored and has infusion pump that controls the volume of the substance to be administered in the body. Increase in incidence of chronic disorders, surge in trauma cases, rise in geriatric population, and growth in road accidents are expected to boost the market growth during the analysis period. However, lack of skilled professionals is projected to restrain the market growth during the forecast period.

The intravenous catheter market segment held the highest share, owing to increase in healthcare expenditure and continuous advancement in intravenous catheter technology, which are expected to support the growth of this market during the forecast period.

Download Free Sample PDF of Report with Details COVID-19 Impact Analysis@ https://www.alliedmarketresearch.com/request-sample/2350

Medical administration held the highest market share in 2018, owing to wide use of IV therapy for medication administration as it is most effective, fast acting, and suitable for unconscious and emergency patients. The hospitals segment gained the highest market share in 2018, owing to highest number of surgical procedures in hospitals resulting in usage of IV therapy.

Market Competitive Analysis:

The major players profiled in the global IV therapy and vein access devices market are Becton, Dickinson and Company, B. Braun Melsungen AG, Terumo Medical Corporation, Teleflex Medical Inc., Medtronic Inc., Smith & Nephew plc., AngioDynamics, Inc., Pfizer Inc., Insulet Corporation, and Fresenius SE & Co. KGaA.

Covid-19 Impact on the Global Intravenous Therapy and Vein Access Market:

Intravenous Therapy and Vein Access Market Report provides an overview of the market based on key parameters such as market size, sales, sales analysis and key drivers. The market size of the market is expected to grow on a large scale during the forecast period (2019-2026). This report covers the impact of the latest COVID-19 on the market. The coronavirus epidemic (COVID-19) has affected all aspects of life around the world. This has changed some of the market situation. The main purpose of the research report is to provide users with a broad view of the market. Initial and future assessments of rapidly.

Key Findings of the Intravenous Therapy and Vein Access Devices Market:

• By product, the intravenous catheter segment dominated the market in 2018, and is projected to grow at the highest CAGR during the analysis period 2020-2026.
• By application, the medication administration segment accounted for the highest share in 2018.
• U.S. was the major shareholder in the North America IV therapy and vein access devices market in 2018.
• Asia-Pacific is expected to witness the highest growth rate.
• China is expected to grow at the highest CAGR in the Asia-Pacific IV therapy and vein access devices market in 2018.

North America accounted for two-fifths share in 2016, and is expected to dominate the market throughout the forecast period. This is attributed to increase in incidence of chronic diseases due to rise in geriatric population, well-established healthcare systems, and increase in awareness among the population toward timely diagnosis and treatment of diseases. In addition, higher adoption rate for technologically advanced devices is anticipated to provide new growth opportunities for the key players in the market. However, Asia-Pacific is projected to grow at the highest growth rate during the analysis period, owing to rise in healthcare expenditure, increase in per capita income, growth in demand for healthcare services from large pool of patient population, and improvement in healthcare infrastructure.

Inquiry for Buying@ https://www.alliedmarketresearch.com/purchase-enquiry/2350

About Us:

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

Shadab Pathan
Allied Market Research
+1 800-792-5285
email us here


Source: EIN Presswire

Digital PCR Market to Reach $1,206.46 Million by 2025 at 18.0% CAGR

Digital PCR Market

Digital PCR Market

Rise in need for early diagnosis of chronic diseases, increase in demand for innovative diagnostic techniques in health are like to growth of digital PCR market

PORTLAND, OR, UNITED STATES, September 23, 2020 /EINPresswire.com/ — Allied Market Research recently published a report, titled, "Digital PCR Market by Technology (Droplet Digital PCR (ddPCR) and BEAMing Digital PCR), Product Type (Digital PCR Equipment, Consumables & Reagents, and Software & Services), Application (Clinical Diagnostics, Research, and Forensics), and End User (Clinical Diagnostic Laboratories, Pharmaceuticals and Biotechnology Industries, and University and Government Organizations): Global Opportunity Analysis and Industry Forecast, 2018–2025". According to the report, the global digital PCR market was pegged at $318.22 million in 2017 and is projected to reach $1,206.46 million by 2025, growing with a CAGR of 18.0% through 2025.

Rise in demand for innovative diagnostic techniques and increase in health awareness have boosted the growth of the global digital PCR market. However, high cost of dPCR testing and limited expertise and accessibility in the emerging economies hinder the market growth. On the contrary, rise in need for early diagnosis of viral, genetic and infectious disease and surge in number of diagnostic centers across the globe are expected to create lucrative opportunities for the market players in the near future.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/654

Droplet digital PCR segment dominates the market

Droplet digital PCR segment held the largest share in 2017, contributing more than four-fifths of the total market. However, the BEAMing digital PCR segment is projected to manifest the fastest CAGR of 18.9% during the forecast period.

Software & services segment to manifest fastest growth by 2025

Software & services segment is projected to portray the fastest CAGR of 19.9% during the study period. However, consumables and reagents segment held the largest share in 2017, contributing more than half of the total market. The report also analyzes the segment of digital PCR systems.

Research segment to retain lion's share

The research segment contributed the largest share, holding nearly one-third of the market in 2017. However, the forensics segment is estimated to manifest the fastest CAGR of 18.8% during the forecast period. The report also studies the segment of clinical diagnostics.

Asia-Pacific region to portray fastest growth through 2025

Asia-Pacific region is projected to register the fastest CAGR of 17.7% during the forecast period, owing to increase in number of patients suffering from chronic diseases and improvement in healthcare facilities in the region. However, the North America region dominated the market in terms of revenue, contributing nearly half of the market, owing to presence of leading molecular diagnostics manufacturers and rise in number of patients using personalized medicines. The report also analyzes the other regions such as Europe and Latin America, Middle East and Africa (LAMEA).

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/654

Major market players

The report analyzes the major companies in the market including Bio-Rad Laboratories, Inc. (RainDance Technologies, Inc.), JN Medsys, Qiagen N.V. (Formulatrix, Inc.), Expedeon AG, Sysmex Corporation (Sysmex Inostics GmbH), Fluidigm Corporation, Merck KGaA, Stilla Technologies, and Thermo Fisher Scientific, Inc.

Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at: https://www.alliedmarketresearch.com/knowledgetree

Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.

Similar Reports:

Global Digital Pathology Market Expected to Reach $1,390 Million by 2026
Global Workplace Wellness Market Expected to Reach $74 Billion by 2026

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire